AGEN Agenus Inc.

4.10
+0.00  (0%)
Previous Close 4.10
Open 4.07
Price To book -22.78
Market Cap 408820450
Shares 99,712,305
Volume 330,539
Short Ratio 10.84
Av. Daily Volume 1,121,459

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 171069236
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171012671
  3. 8-K - Current report 171003006
  4. 8-K - Current report 17942256
  5. CT ORDER - Confidential treatment order 17920369

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

BLA filing announced October 24, 2016. PDUFA estimate October 24, 2017. Advisory Committee Meeting September 13, 2017 voted 11-0 in favor. Shingrix, containing Agenus' adjuvant, QS-21 Stimulon.
Shingrix
Shingles
Phase 1/2 initiation announced April 20, 2017.
AGEN2034
Solid tumors
Phase 1/2 trial initiation announced November 30, 2016.
INCAGN1949
Solid tumors - cancer
Phase 1/2 trial commenced June 2016
INCAGN1876
Solid tumors - cancer

SEC Filings

  1. CT ORDER - Confidential treatment order 171069236
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171012671
  3. 8-K - Current report 171003006
  4. 8-K - Current report 17942256
  5. CT ORDER - Confidential treatment order 17920369
  6. CT ORDER - Confidential treatment order 17894105
  7. DEF 14A - Other definitive proxy statements 17822245
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814039
  9. 8-K - Current report 17812091
  10. 8-K - Current report 17771533